- Merck KGaA‘s adjusted Ebitda for the fiscal year met estimates at EU5.88 billion, just under the estimated EU5.9 billion.
- The adjusted Ebitda margin was 28%, slightly down from 30.8% year-over-year (y/y).
- Adjusted EPS (Earnings Per Share) came in at EU8.49.
- Net income was EU2.83 billion, a 15% decrease y/y, matching the estimate of EU2.83 billion.
- Dividend per share was EU2.20, slightly above the estimated EU2.19.
- Net sales reached EU20.99 billion, falling just short of the estimated EU21.01 billion.
- Mavenclad sales increased by 12% y/y to EU956 million, surpassing the estimated EU920.8 million.
- Rebif sales were at EU709 million, also beating the estimate of EU684.9 million.
- Bavencio sales rose by 17% y/y to EU713 million, higher than the estimated EU704.6 million.
- Merck KGaA is forecasting a return to organic growth in 2024.
- The company expects slight to moderate organic growth in fiscal year sales and adjusted Ebitda.
- Fiscal year earnings growth is expected to be primarily driven by the Healthcare business.
A look at Merck KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Merck KGaA, a global pharmaceutical and chemicals company, has a positive outlook for the long-term. According to Smartkarma Smart Scores, the company received a score of 4 for Growth, indicating strong potential for future expansion and development. Merck KGaA also received a score of 4 for Momentum, suggesting that it is performing well in the current market. With a score of 3 for Value, the company is deemed to have a fair valuation, making it a potentially attractive investment opportunity. Additionally, Merck KGaA received a score of 3 for Dividend, indicating a stable and consistent dividend payout to investors. With a score of 3 for Resilience, the company is expected to withstand market fluctuations and maintain a stable performance. Overall, Merck KGaA‘s Smartkarma Smart Scores suggest a positive outlook for the company’s future growth and performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
